Q4 EPS Forecast for CRISPR Therapeutics Boosted by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Brookline Capital Management increased their Q4 2025 earnings estimates for shares of CRISPR Therapeutics in a report released on Monday, November 10th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of ($0.81) for the quarter, up from their previous forecast of ($1.27). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ FY2028 earnings at $8.70 EPS and FY2029 earnings at $41.58 EPS.

CRSP has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, October 8th. JPMorgan Chase & Co. began coverage on shares of CRISPR Therapeutics in a research note on Thursday, September 18th. They issued an “overweight” rating and a $70.00 target price for the company. Bank of America increased their price target on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Wells Fargo & Company set a $75.00 price target on CRISPR Therapeutics in a research note on Monday, October 13th. Finally, Zacks Research raised CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Eleven analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $68.11.

CRISPR Therapeutics Trading Up 1.2%

CRISPR Therapeutics stock opened at $55.21 on Wednesday. The stock has a 50-day moving average price of $63.03 and a two-hundred day moving average price of $53.45. CRISPR Therapeutics has a 12 month low of $30.04 and a 12 month high of $78.48. The company has a market capitalization of $5.02 billion, a PE ratio of -9.88 and a beta of 1.89.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.49%. The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $8.74 million.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total value of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares of the company’s stock, valued at $5,554,573.20. The trade was a 1.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 50,895 shares of the stock in a transaction on Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer directly owned 254,201 shares of the company’s stock, valued at $17,262,789.91. The trade was a 16.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 56,213 shares of company stock worth $3,810,458. 4.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. SVB Wealth LLC purchased a new stake in shares of CRISPR Therapeutics in the 1st quarter worth about $25,000. Costello Asset Management INC purchased a new position in CRISPR Therapeutics in the 1st quarter worth about $27,000. Atlantic Union Bankshares Corp purchased a new stake in CRISPR Therapeutics in the second quarter worth approximately $33,000. Thompson Investment Management Inc. bought a new position in CRISPR Therapeutics in the third quarter valued at about $33,000. Finally, Optiver Holding B.V. boosted its holdings in shares of CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after buying an additional 210 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.